1. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Issue 12 (December 2020) Authors: Rocconi, Rodney P; Grosen, Elizabeth A; Ghamande, Sharad A; Chan, John K; Barve, Minal A; Oh, Jonathan; Tewari, Devansu; Morris, Peter C; Stevens, Erin E; Bottsford-Miller, Justin N; Tang, Min; Aaron, Phylicia; Stanbery, Laura; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Manning, Luisa; N... Journal: Lancet oncology Issue: Volume 21:Issue 12(2020) Page Start: 1661 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Issue 3 (March 2021) Authors: Rocconi, Rodney P.; Grosen, Elizabeth A.; Ghamande, Sharad A.; Chan, John K.; Barve, Minal A.; Oh, Jonathan; Tewari, Devansu; Morris, Peter C.; Stevens, Erin E.; Bottsford-Miller, Justin N.; Tang, Min; Aaron, Phylicia; Stanbery, Laura; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Manning, ... Journal: Obstetrical & gynecological survey Issue: Volume 76:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. Issue 3 (March 2021) Authors: Rocconi, Rodney P.; Grosen, Elizabeth A.; Ghamande, Sharad A.; Chan, John K.; Barve, Minal A.; Oh, Jonathan; Tewari, Devansu; Morris, Peter C.; Stevens, Erin E.; Bottsford-Miller, Justin N.; Tang, Min; Aaron, Phylicia; Stanbery, Laura; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Manning, ... Journal: Obstetrical & gynecological survey Issue: Volume 76:Issue 3(2021) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. (August 2022) Authors: Barve, Minal; Aaron, Phylicia; Manning, Luisa; Bognar, Ernest; Wallraven, Gladice; Horvath, Staci; Stanbery, Laura; Nemunaitis, John Journal: Clinical medicine insights. Oncology Issue: Volume 16(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗